Consistent with the in vitro experiments, we demonstrated that compound 968 combined with anti-PD-L1 antibody had a beneficial therapeutic effect on ovarian cancer by increasing the cytolytic potential of immune cells. This evidence concerns the gene CD274 and ovarian carcinoma.